Sun-Novo(SH:688621) 智通财经网·2025-12-11 08:21Core Viewpoint - The company, Sunlight Nuohe (688621.SH), is making a strategic investment of 20 million yuan in Shanghai Biling Biotechnology Co., Ltd. to enhance its position in the innovative drug industry, particularly in the field of novel nano-conjugated drugs and precise nano-delivery systems [1] Investment Details - The company will invest 20 million yuan to subscribe for an additional registered capital of 82,661 yuan in Biling Biotechnology, resulting in a 2.0435% equity stake in the company [1] - This investment is part of the company's broader strategy to strengthen its innovative drug industry chain [1] Technology and Market Potential - Biling Biotechnology specializes in novel nano-conjugated drugs and precise nano-delivery systems, which have significant application prospects in treating major diseases such as cancer [1] - The core technology platform of Biling can effectively enhance drug targeting and delivery efficiency, indicating a strong market potential [1] Strategic Alignment - The investment allows the company to enter the cutting-edge nano-drug technology sector, creating synergies with its existing business [1] - This move is expected to enrich the company's technological reserves and pipeline layout in innovative drug research and development, thereby enhancing its overall competitiveness in the pharmaceutical industry [1]